570 related articles for article (PubMed ID: 12083975)
1. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of classical and new antipsychotic drugs.
Otani K; Aoshima T
Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
Scordo MG; Spina E
Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
6. High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report.
Mian P; Somers M; Berg MT; Cahn W; Wilting I; Schaik RV
Pharmacogenomics; 2019 Jun; 20(8):567-570. PubMed ID: 31190622
[TBL] [Abstract][Full Text] [Related]
7. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
8. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
[TBL] [Abstract][Full Text] [Related]
11. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
[TBL] [Abstract][Full Text] [Related]
12. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
Murray M
J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
[TBL] [Abstract][Full Text] [Related]
15. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
16. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
18. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
19. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
Tanaka E; Kurata N; Yasuhara H
J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]